United Therapeutics Corporation (UTHR) Balance Sheet

Total equity has expanded steadily from $5.7B in 2024Q2 to $6.3B in 2026Q3, driven largely by retained earnings growth from $6.6B to $9.4B. The recent sequential cash decline alongside rising assets suggests capital is being redeployed into acquisitions and pipeline investment, which warrants investigation into whether those outlays are generating returns commensurate with the cash consumed.

A current ratio well above 4 indicates ample short-term coverage of liabilities, and total liabilities of $758.1M are modest relative to the asset base. However, the cash balance has oscillated between $1.1B and $1.9B over recent quarters, and investors should monitor whether the 2026Q3 decline reflects a sustained trend or timing of acquisition outflows.

The progressive repayment of debt from $500M to zero over roughly six quarters suggests a deliberate deleveraging strategy rather than a necessity-driven one. With debt effectively eliminated, cash flow durability is not constrained by debt service, though the firm's financial flexibility now depends more heavily on operating cash generation.

The asset mix points to a business whose value rests primarily on its commercial franchise and manufacturing footprint rather than on purchased goodwill, which reduces the risk of a sizeable write-down. The steady rise in PP&E from $1.2B in 2024Q4 to $2.0B in 2026Q3 is consistent with the capital intensity increase flagged in the cash flow analysis, and warrants monitoring for returns on that infrastructure.